We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Medical Center Collaborates with GenomeQuest

By LabMedica International staff writers
Posted on 14 Jan 2013
GenomeQuest, Inc. More...
(Westborough, MA, USA) a leader in sequence data management, and Beth Israel Deaconess Medical Center (BIDMC; Boston, MA, USA), a Harvard Medical School teaching hospital, are entering into a two-year collaboration to develop whole-genome analysis (WGA) applications for personalized health care. The announcement was made during the opening session of the World Health Forum, held at Harvard Medical School, on December 20, 2012, in Boston (MA, USA).

GenomeQuest will provide whole-genome data management and analysis capabilities for all next-generation sequencing projects in BIDMC’s dept. of pathology. GenomeQuest will also provide application programming interface (API) access and training to the department’s scientific investigators and applied mathematicians. BIDMC pathologists will develop clinical grade annotation methods and databases for diagnoses of cancers and other diseases. Collaborative projects will span user interface, workflows, sequence, and annotation management, and integration into health care Information Technology (IT) systems.

“The latest PriceWaterHouseCoopers report on personalized medicine estimates that this market will grow to nearly $500 billion in 2015 and terms it a ‘disruptive innovation’ for life sciences,” explained BIDMC chief of pathology Jeffrey Saffitz, MD, PhD. “The BIDMC pathology department is already a national leader in the development and application of genomics for personalized medicine, having launched its Genomic Medicine Training Initiative one year ago, and, this past spring, issuing a ‘Call to Action’ for pathology training programs across North America to do the same. Our collaboration with GenomeQuest helps provide us with the infrastructure to continue this work.”

Beth Israel Deaconess Medical Center is clinically affiliated with the Joslin Diabetes Center and is a research partner of the Dana-Farber/Harvard Cancer Center. The core technology of GenomeQuest is the GQ-Engine–a sequence database engine that is purpose-built for storing, managing, and analyzing sequence data at whole- and multigenome scale.

Related Links:
GenomeQuest, Inc.
Beth Israel Deaconess Medical Center


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.